Pharmacokinetic Clinical Reaserch of EVG/COBI/FTC/TAF FDC -Food effect on Pharmacokinetic Profiles in Japanese Healthy Adult Male Volunteers-

Trial Profile

Pharmacokinetic Clinical Reaserch of EVG/COBI/FTC/TAF FDC -Food effect on Pharmacokinetic Profiles in Japanese Healthy Adult Male Volunteers-

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 01 Jan 2018 Results assessing food effect on pharmacokinetics profiles of elvitegravir and cobicistat administered as EVG/COBI/FTC/TAF FDC in healthy Japanese adult male volunteers, were published in the Clinical Pharmacology in Drug Development.
    • 01 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top